Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17088202 | 0.90 | PDE10A (0.57) | PDE10ASLC6A3 | |
| SCHEMBL11996181 | 0.87 | PDE10A (0.74) | PDE10ASLC6A3 | |
| SCHEMBL24951258 | 0.86 | PDE10A (0.53) | PDE10ASLC6A3 | |
| SCHEMBL1758710 | 0.86 | PDE10A (0.71) | PDE10A | |
| SCHEMBL1758488 | 0.84 | PDE10A (0.52) | PDE10ASLC6A3 | |
| SCHEMBL17088195 | 0.84 | SLC6A3 (0.69) | PDE10ASLC6A3 | |
| SCHEMBL3276042 | 0.84 | PDE10A (0.69) | PDE10A | |
| SCHEMBL17088197 | 0.84 | SLC6A3 (0.69) | PDE10ASLC6A3 | |
| SCHEMBL17089021 | 0.83 | SLC6A3 (0.67) | PDE10ASLC6A3 | |
| SCHEMBL17088203 | 0.83 | PDE10A (0.51) | PDE10ASLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160058894-A1 | RADIOLABELED PDE10A LIGANDS | ABBVIE DEUTSCHLAND (DE) | 2016-03-03 | — | — | US | disclosed |
| US-20160058894-A1 | RADIOLABELED PDE10A LIGANDS | ABBVIE DEUTSCHLAND (DE) | 2016-03-03 | — | — | US | disclosed |
| US-9138494-B2 | Radiolabeled PDE10A ligands | ABBVIE INC. (US) | 2015-09-22 | — | — | US | disclosed |
| US-9138494-B2 | Radiolabeled PDE10A ligands | ABBVIE INC. (US) | 2015-09-22 | — | — | US | disclosed |
| US-8852554-B2 | Radiolabelled PDE10 ligands | JANSSEN PHARMACEUTICA NV (BE) | 2014-10-07 | — | — | US | disclosed |
| US-8852554-B2 | Radiolabelled PDE10 ligands | JANSSEN PHARMACEUTICA NV (BE) | 2014-10-07 | — | — | US | disclosed |
| US-8852554-B2 | Radiolabelled PDE10 ligands | JANSSEN PHARMACEUTICA NV (BE) | 2014-10-07 | — | — | US | disclosed |
| EP-2493513-B1 | RADIOLABELLED PDE10 LIGANDS | JANSSEN PHARMACEUTICA NV (BE) | 2014-07-30 | — | — | EP | disclosed |
| EP-2493513-B1 | RADIOLABELLED PDE10 LIGANDS | JANSSEN PHARMACEUTICA NV (BE) | 2014-07-30 | — | — | EP | disclosed |
| EP-2493513-A1 | RADIOLABELLED PDE10 LIGANDS | Janssen Pharmaceutica, N.V. (BE) | 2012-09-05 | — | — | EP | disclosed |
| US-20120213703-A1 | RADIOLABELLED PDE10 LIGANDS | JANSSEN-CILAG S.A., EDIFICIO JOHNSON & JOHNSON (ES) | 2012-08-23 | — | — | US | disclosed |
| US-20120213703-A1 | RADIOLABELLED PDE10 LIGANDS | JANSSEN-CILAG S.A., EDIFICIO JOHNSON & JOHNSON (ES) | 2012-08-23 | — | — | US | disclosed |
| US-20120213703-A1 | RADIOLABELLED PDE10 LIGANDS | JANSSEN-CILAG S.A., EDIFICIO JOHNSON & JOHNSON (ES) | 2012-08-23 | — | — | US | disclosed |
| WO-2011051324-A1 | RADIOLABELLED PDE10 LIGANDS | JANSSEN PHARMACEUTICA NV (BE) | 2011-05-05 | — | — | WO | disclosed |
| WO-2011051324-A1 | RADIOLABELLED PDE10 LIGANDS | JANSSEN PHARMACEUTICA NV (BE) | 2011-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160058894-A1 | RADIOLABELED PDE10A LIGANDS | PDE10A, PDE3A, PDE5A | PDE10A 1/4885SLC6A3 901/4885 |
| US-20120213703-A1 | RADIOLABELLED PDE10 LIGANDS | PDE9A, PDE10A, PDE7A | PDE10A 2/4885SLC6A3 635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.